Objective： To identify and localize the synthesized targeting peptide A54 to liver cancer cell line BEL-7402 in vivo and in vitro for confirming the potential clinical application of peptide A54 in hepatocarcinoma ta...Objective： To identify and localize the synthesized targeting peptide A54 to liver cancer cell line BEL-7402 in vivo and in vitro for confirming the potential clinical application of peptide A54 in hepatocarcinoma targeting therapy. Methods： Phage A54 was confirmed by ELISA. Biotin and FAM labeled A54 peptides were identified and localized by means of jmmunohistochemistry and immunocytochemistry. Results： A54 peptide could target the liver-rumor tissue in vivo and adhere to several liver-rumor cells in vitro. FAM-labeled A54 peptides were localized on the membrane surface of liver-rumor cells. Conclusion： Synthesized A54 peptide obtained from in vivo phage display technology still kept special abilityto adhere liver-rumor cell in vivo and in vitro. The A54 peptide could be a candidate carrier for hepatocarcinoma targeting therapy.展开更多
基金This work was supported by ShanghaScientific Development Foundation (04JC14033), the NationaNatural Science Foundation of China(No. 30440039), the "Shuguang" Project of Shanghai Municipal Education Commissionand Shanghai Education Development Foundation (02SG21).
文摘Objective： To identify and localize the synthesized targeting peptide A54 to liver cancer cell line BEL-7402 in vivo and in vitro for confirming the potential clinical application of peptide A54 in hepatocarcinoma targeting therapy. Methods： Phage A54 was confirmed by ELISA. Biotin and FAM labeled A54 peptides were identified and localized by means of jmmunohistochemistry and immunocytochemistry. Results： A54 peptide could target the liver-rumor tissue in vivo and adhere to several liver-rumor cells in vitro. FAM-labeled A54 peptides were localized on the membrane surface of liver-rumor cells. Conclusion： Synthesized A54 peptide obtained from in vivo phage display technology still kept special abilityto adhere liver-rumor cell in vivo and in vitro. The A54 peptide could be a candidate carrier for hepatocarcinoma targeting therapy.
